Edwards Adds To Wide Range Of Approaches To Mitral Repair

Dec 12 2017

• By Reed Miller

Listen to this article

Harpoon is a minimally invasive surgery device that complements Edwards pipeline of transcatheter mitral and septal valve repair and replacement technologies, which now includes at least six technologies at various stages of development, and is one of the company's top R&D priorities.

Less-invasive mitral valve and tricuspid valve repair is the next major for valve technology now that transcatheter aortic valve replacement (TAVR) systems, like Edwards' market-leading Sapien line, are rapidly taking market share from surgical valves, and is being pursued both by the major surgical valve companies, Edwards and Medtronic PLC as well as small start-ups like 4C Medical Technologies and MVRx, Inc. But Abbott Laboratories Inc.'s MitraClip is the only FDA-approved transcatheter mitral repair device. (Also see "Starts & Stops: Medtronic's TMVR News Closes Big Month For Trial Announcements" - Medtech Insight, 3 November, 2017.)

"We are aggressively pursuing a whole toolbox of therapies for mitral and tricuspid therapies," Edwards CEO Michael Mussallem said during...

More from Deals

Investor Eye: Intuitive Surgical Hops, Skips, And Jumps Into VC
Oct 17 2025
• By Barnaby Pickering
When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.
test carousel-Medtech
Oct 14 2025
• By Saba Afreen
test carousel-Medtech
MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain
Jun 14 2025
• By Nabil
Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.
Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool
Oct 02 2024
• By Natasha Barrow
Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

More from Business

test carousel-Medtech
Oct 14 2025
• By Saba Afreen
test carousel-Medtech
test carousel
Oct 14 2025
• By Saba Afreen and Krsihna
test carousel-HBW
News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards
Sep 30 2025
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.